Peptide News
Breaking research, regulatory changes, and industry developments in the world of peptides.
FDA Schedules July 2026 PCAC Review of BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon, DSIP
The FDA Pharmacy Compounding Advisory Committee will review BPC-157, TB-500, MOTs-C, KPV, Semax, Epitalon and DSIP for the 503A bulks list in July 2026.
Tirzepatide Cardiovascular Outcomes: Two New Studies Examine Heart Risk Effects
Two recent studies looked at tirzepatide, a dual GIP/GLP-1 receptor agonist, in patients with elevated cardiovascular risk. Here's what the evidence shows.
HYTN Announces Proposed Spin-Out of BPC-157 Peptide Drug Development Business
HYTN Innovations plans to spin out its BPC-157 peptide drug development arm into a separate entity, signaling a sharper focus on the regulated peptide pipeline.
Lexaria Launches Second Animal Study on Oral Amycretin and Retatrutide
Lexaria starts a second animal study testing whether its DehydraTECH platform can improve next-generation GLP-1 drugs amycretin and retatrutide.
GLP-1 Receptor Agonists Show Promise for Stroke Prevention in Type 2 Diabetes
A new narrative review on PubMed examines how GLP-1 receptor agonists may help prevent stroke in people with type 2 diabetes, covering trials and mechanisms.
Researchers Spot a 'Natural Ozempic' Pathway in the Gut
Scientists have identified a gut-derived molecule that appears to trigger GLP-1 release the same way Ozempic does, opening doors to food-based weight control.
Melanotan 2 Remains One of the Most Discussed Peptides in 2026
Melanotan 2 continues to attract attention for its tanning and appetite effects, but safety concerns and regulatory gray areas keep it controversial.
Study Finds Nutritional Risks in Users of GLP-1 Drugs
New research highlights potential vitamin and mineral deficiencies among patients taking GLP-1 receptor agonists for weight loss, raising questions about long-term supplementation needs.
Heart Benefits of GLP-1 Medications Fade Shortly After Stopping Therapy
New research finds that cardiovascular protection from GLP-1 drugs like semaglutide and tirzepatide diminishes within months of discontinuation.
Genetics reveal why people respond differently to GLP-1 weight-loss drugs
New research links genetic variants in GLP1R and GIPR to differences in how patients respond to GLP-1 medications, pointing toward more personalized treatment.
Retatrutide Hits All Primary Endpoints in Phase 3 Type 2 Diabetes Trial
Eli Lilly's triple agonist retatrutide delivered significant A1C reductions and weight loss in the TRANSCEND-T2D-1 trial, marking a major step toward approval.
APhA 2026: GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease
At APhA 2026, Emily Eddy, PharmD, mapped the expanding reach of incretin therapies beyond obesity into liver, kidney, and addiction medicine.
Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
Wall Street remains skeptical, but developers of amylin-based drugs say recent clinical trial results point to a real opening in the weight-loss market.
GLP-1 Receptor Agonists Linked to Cervical Spinal Fusion Outcomes in New Cohort Study
A large retrospective cohort study examines how GLP-1 receptor agonist use affects perioperative outcomes in patients undergoing posterior cervical spinal fusion.
Retatrutide Delivers Significant A1C Reduction, Weight Loss in Phase 3 Type 2 Diabetes Trial
Eli Lilly's retatrutide hit its primary endpoint in a Phase 3 trial, showing superior A1C reduction and weight loss in adults with type 2 diabetes at 40 weeks.
A Physician Makes the Case for Peptide Therapy — and Admits the Evidence Gaps
A functional medicine doctor explains why they prescribe peptides like BPC-157 despite limited human trials, and the professional risk of saying so publicly.
The Weight-Loss Drug Rivalry Heats Up as Another GLP-1 Pill Gains FDA Approval
The FDA has approved Foundayo, a second oral GLP-1 drug for weight loss, adding a new pill option to a market long dominated by injectable treatments.
FDA Approves First GLP-1 Pill for Obesity: Eli Lilly's Orforglipron Changes the Game
The FDA has approved orforglipron (Foundayo), the first oral small-molecule GLP-1 receptor agonist for weight loss. Here's what it means for the future of obesity treatment and the peptide space.
FDA Data Reveal Different Risks for GLP-1s
GLP-1s are linked to a broad range of adverse events — largely gastrointestinal, metabolic, and psychological — across indications, according to analysis of FDA
Did BPC-157 and TB-500 help you with tennis elbow?
Did BPC-157 and TB-500 help you with tennis elbow?
US FDA clarifies policies on compounding of GLP-1 medicines | Reuters
The U.S. Food and Drug Administration on Wednesday clarified its policies on compounded versions of popular GLP-1 drugs, signaling tighter limits on their prod
FDA approves GLP-1 weight loss pill Foundayo from Eli Lilly
A new daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the FDA approval of Novo Nordisk’s Wegovy pill.
FDA ready to allow compounding pharmacies to make injectable peptides - report - Seeking Alpha
FDA ready to allow compounding pharmacies to make injectable peptides - report - Seeking Alpha
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online - 2026 Search Trends and Publicly Available Pricing Information Context
MEDVi tirzepatide GLP-1 pricing, compounded medication access, telehealth structure, and 2026 regulatory context based on publicly available info...
FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Take Down. What’s Next? | Pharmacy Times
FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo sues Hims & Hers and regulators hint at seizures.
FDA Peptide Reclassification: 14 Restricted Peptides Moving Back to Legal Status
HHS Secretary RFK Jr. announces 14 of 19 restricted peptides will return to Category 1, restoring access through licensed compounding pharmacies. Here's what's changing and which peptides are coming back.
OrbiMed-Backed Pinnacle Raises $89M Series B to Advance Oral Peptide Pipeline
Pinnacle has closed an $89M Series B round backed by OrbiMed to fund development of its oral peptide drug candidates, a growing area of biotech investment.
The Science of GLP-1s: How Semaglutide and Tirzepatide Mimic Natural Hormones to Curb Hunger.
Hunger is a powerful force that drives eating behavior, but for many people, controlling appetite can be a major challenge. Recent advances in medicine have int
Amazon Pharmacy Adds FDA-Approved Wegovy Pill, the First Oral GLP-1 for Weight Loss | Pharmaceutical Commerce
Novo Nordisk’s newly approved oral semaglutide is now available nationwide through Amazon Pharmacy with insurance and cash-pay options.
Peptide Protocol for Weight Loss in Indiana (IN) | FDA-Approved Peptide Therapy Online
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence
Peptide Sciences Shuts Down Operations, Citing Voluntary Decision
Major research peptide supplier Peptide Sciences says it has voluntarily ceased operations and discontinued all research product sales.
GLP-1 Drugs Show Benefits in Cushing Syndrome
Emerging research suggests GLP-1 receptor agonists may help manage the stubborn metabolic complications of Cushing syndrome, from insulin resistance to weight gain.
GLP-1s Linked to Lower Mortality in Patients With Brain Mets
An observational study reported by Medscape found that patients with brain metastases who were taking GLP-1 receptor agonists had better survival outcomes than those who were not.
FDA Issues New Warning Letter to Compounders Over Semaglutide Salt Products
The FDA warned compounders still marketing semaglutide salt products, saying they aren't the same active ingredient found in approved GLP-1 medications.
GLP-1s a Viable Option to Treat, Prevent SUDs?
New research explores whether GLP-1 receptor agonists could help treat and prevent substance use disorders, opening a surprising new frontier for the drug class.
Pancreatic Enzyme Replacement Therapy for GLP-1 Symptoms?
Medscape explores whether pancreatic enzyme replacement therapy could help manage the gastrointestinal side effects commonly reported by GLP-1 medication users.
Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1
Structure Therapeutics shares additional Phase 2 results for its oral GLP-1 receptor agonist, adding to the growing pipeline of non-injectable weight loss treatments.
Structure Touts 16% Weight Loss for Aleniglipron, Calling It the Most Effective Oral GLP-1 Yet
Structure Therapeutics reports aleniglipron delivered up to 16.3% placebo-adjusted weight loss in Phase 2 trials, positioning the oral GLP-1 pill for Phase 3 in mid-2026.
FDA Peptide Reclassification: A New Era for Compounding Pharmacies?
HHS Secretary Robert F. Kennedy Jr.'s recent comments hint at a significant shift in FDA peptide regulation, potentially opening new avenues for compounding pharmacies and reshaping the market.
FDA Intensifies Scrutiny on Compounded GLP-1 Drugs
The FDA is cracking down on compounded GLP-1 drugs for weight loss, citing concerns over active pharmaceutical ingredients and manufacturing standards.
New Imaging Technique Sheds Light on Peptide Structures
Researchers develop a chemical probe to differentiate synthetic peptides from neurotoxic types, offering new insights into diseases like Alzheimer's.
RFK Jr. Plans to Unleash Banned Peptides in Bold FDA Challenge
Robert F. Kennedy Jr. announces intentions to reverse FDA restrictions on nearly two dozen peptides if elected president, sparking significant debate.
Biweekly GLP-1 candidate bofanglutide shows 9.8% to 16.7% weight loss at 30 weeks in phase 2b trial
A Feb 27 PubMed report describes a randomized phase 2b trial of bofanglutide, a once-every-two-weeks GLP-1 receptor agonist, with double-digit average weight loss and mostly mild GI side effects.
A new analysis links slower GLP-1 dose escalation to better nausea tolerance and stronger weight loss
A Feb 27 PubMed paper suggests that longer, stepwise titration schedules may help patients tolerate higher doses of semaglutide and tirzepatide, with bigger effects on A1c and weight.
Rare but serious: a new case report describes probable tirzepatide-associated rhabdomyolysis
A Feb 23 case report describes rhabdomyolysis symptoms emerging after starting tirzepatide for weight loss, with improvement after stopping the drug and receiving IV fluids.
FDA signals tougher action on mass-marketed compounded GLP-1s
A new FDA statement (Feb 6, 2026) targets non-approved GLP-1 compounded products and the marketing claims around them, raising the compliance stakes for clinics and compounders.
Copper peptides (GHK-Cu) are having a moment in skincare
A luxury skincare story is pushing GHK-Cu back into the spotlight. Here’s what the copper peptide is, what the research suggests, and where the hype can outrun the data.
Peptides are everywhere, but the evidence is uneven
Mainstream outlets are finally covering the peptide boom. Here’s what they’re getting right, what they’re missing, and why quality and clinical data matter more than hype.
BPC-157 Hits the Mainstream Again, Right as Regulators Keep Tightening the Screws
A new Men’s Health feature shows how BPC-157 went from niche biohacker peptide to cultural headline, while FDA and WADA restrictions keep widening the gap between hype and evidence.
FDA Signals Enforcement on Mass-Marketed Compounded GLP-1s as Novo Nordisk Sues Hims & Hers
A fresh FDA statement targets non-FDA-approved compounded GLP-1 drugs being mass-marketed, and a new Novo Nordisk lawsuit ramps up pressure on telehealth and compounding players.
New 2026 Review Maps the Peptide-Protein Docking Toolchain (and Why It Matters for Therapeutics)
A new Journal of Computational Chemistry review catalogs peptide-protein docking software and AI alternatives, offering a practical snapshot of what works, what breaks, and where the field is headed.
GLP-1 Peptides Are Being Studied for Brain Protection — And the Data Is Getting Harder to Ignore
New analysis finds GLP-1 receptor agonists show neuroprotective effects in Alzheimer's, Parkinson's, and traumatic brain injury models. The brain connection was always there — researchers are finally taking it seriously.
FDA Approves First Oral Semaglutide Pill for Weight Loss — A Turning Point for GLP-1 Therapy
The FDA cleared oral Wegovy (semaglutide 25 mg) for chronic weight management on February 18, 2026, making it the first GLP-1 pill approved for obesity. Here's what it means.
Peptide Compounding in 2026: Where the Crackdown Stands and What's At Stake
BPC-157, TB-500, CJC-1295, and dozens of other peptides remain effectively off-limits for compounding pharmacies. Here's the current regulatory picture and what's changing.
FDA Targets Compounded GLP-1s: A Clampdown on Unapproved Weight Loss Products
The FDA is taking decisive action to restrict the mass marketing of compounded GLP-1 active pharmaceutical ingredients, signaling a stricter stance on unapproved weight loss medications.
Oral Semaglutide Approved by FDA, Reshaping Weight Management Landscape
The FDA has given the green light to oral semaglutide as the first-ever GLP-1 pill for weight loss, a move poised to revolutionize treatment accessibility.
Reddit's Most Discussed Peptides of Early 2026: BPC-157 Still Dominates
Analysis of r/peptides discussion trends shows BPC-157 maintaining its lead, with semaglutide and TB-500 close behind. We break down the community's evolving interests.
FDA Cracks Down on Compounding Pharmacies Selling Semaglutide and Tirzepatide
The FDA intensifies enforcement against compounding pharmacies selling semaglutide and tirzepatide as drug shortages end.
Peptide Community Buzzing About FOXO4-DRI After New Longevity Data
Growing interest in the senolytic peptide FOXO4-DRI after new pre-clinical longevity data emerges. What the buzz is about.
New Study Shows BPC-157 Accelerates Tendon Healing in Human Trial
New human trial data shows BPC-157 accelerates tendon healing by 40%. What the research means for the peptide community.
Australia Tightens Regulations on Peptide Imports: What Changed in 2026
New TGA regulations crack down on personal peptide imports, requiring declarations and limiting quantities. Here's what Australian peptide users need to know.
Retatrutide Phase 3 Trial Enrollment Begins: What We Know So Far
Eli Lilly begins phase 3 enrollment for retatrutide, the triple agonist that achieved 24% weight loss in phase 2 trials.
5-Amino-1MQ Shows Promise in New Obesity Research
Recent study demonstrates 5-Amino-1MQ's unique mechanism for weight loss through NNMT inhibition, offering potential advantages over GLP-1 agonists.
The Rise of Peptide Clinics: Telemedicine Meets Peptide Therapy
Online peptide clinics are booming, offering remote consultations and prescriptions. We examine the benefits, risks, and how to identify legitimate providers.